
Lumexa Imaging Holdings, Inc.
70
Lumexa Imaging reported profitability in Q3 2026 with net income of $7 million, driven by increased outpatient volume and announced plans to open three new imaging centers. The company continues to engage with investors through earnings calls and maintains liquidity with a current ratio of 1.52 as of September 30, 2026.
- Lumexa Imaging turned a profit in Q3 2026, reporting $7 million net income attributed to increased outpatient volume [N1].
- The company announced plans to open three new imaging centers, indicating expansion efforts [N1].
- Q3 2026 earnings call transcripts provide detailed insights into operational performance and strategic initiatives [N2, N3].
- Liquidity as of September 30, 2026, includes $90 million in cash and cash equivalents, with a current ratio of 1.52 and cash ratio of 0.49 [S2].
- Management disclosed ongoing professional liability litigation typical for the industry but does not expect material adverse effects [S1].
Lumexa Imaging Holdings, Inc. operates in the medical imaging sector, providing outpatient imaging services. The company has demonstrated profitability in recent quarters and is expanding its physical presence by opening new imaging centers. It maintains liquidity with a current ratio above 1.5 and cash reserves near $90 million as of Q3 2026. Lumexa engages regularly with investors through earnings calls and public disclosures.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Lumexa Imaging Holdings, Inc. reported net income of $7.178 million and EPS of $0.07 for Q3 2026, with liquidity ratios indicating a current ratio of 1.52 and cash ratio of 0.49 as of September 30, 2026 [S2]. The company announced profitability in Q3 driven by increased outpatient volume and plans to open three new centers [N1].
Lumexa's recent profitability and plans to open three new imaging centers indicate operational momentum and potential for increased market penetration. The company's liquidity position supports ongoing expansion and operational stability. Regular investor communications and analyst coverage suggest market interest and transparency.
Lumexa faces typical industry risks including professional liability litigation and regulatory scrutiny, which could impact financials. The absence of detailed revenue disclosures and sector classification limits full visibility into business scale and competitive positioning. Expansion plans carry execution risks and potential capital requirements.
Lumexa's moat appears to be based on its outpatient imaging service network and operational expansion, which may provide competitive advantages in accessibility and patient volume. The company's ability to turn a profit and expand centers suggests operational efficiency and market demand. However, detailed information on proprietary technology or unique service offerings is not disclosed.
• Legal and Regulatory Risks: The company is subject to professional liability litigation and government investigations typical in the healthcare sector. While management does not expect material adverse effects, these risks could impact financial condition [S1].
• Operational Expansion Risks: Plans to open three new imaging centers involve execution risks including capital expenditure, market acceptance, and operational integration [N1].
• Limited Financial Disclosure: Key financial metrics such as revenue are not disclosed in the latest filings, limiting comprehensive assessment of business scale and growth.
Business trends: Increasing outpatient volume and profitability with expansion into new imaging centers.
Execution milestones: Opening three new centers and maintaining liquidity above 1.5 current ratio.
Key risks: Legal and regulatory challenges, execution risks in expansion, and limited financial disclosure.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Lumexa Imaging Holdings, Inc. operates in the medical imaging sector, focusing on outpatient imaging services.
- The company reported net income of $7.178 million for the quarter ended September 30, 2026, with basic and diluted EPS of $0.07 per share as per its 10-Q filing dated November 12, 2026 [S2].
- As of September 30, 2026, Lumexa had cash and cash equivalents of approximately $90 million and current assets totaling $278.3 million, against current liabilities of $183.5 million, resulting in a current ratio of 1.52 and a cash ratio of 0.49 [S2].
- Lumexa turned a profit in Q3 2026, reporting $7 million net income driven by increased outpatient volume and announced plans to open three new imaging centers [N1].
- The company regularly conducts earnings calls and provides transcripts, indicating ongoing communication with investors and stakeholders [N2, N3, N5, N6].
- Lumexa is subject to litigation typical for its business, mainly professional liability claims, with management not expecting material adverse effects from ongoing legal matters [S1].
- Recent news coverage highlights analyst interest and industry outlooks mentioning Lumexa alongside peers, indicating some market attention [N4, N7, N8].
Generated 2026-11-15
- N2
- N3
- N5
- N6
- S1
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-11 | www.nasdaq.com | Lumexa Turns Profit In Q3 At $7 Mln With Increased Outpatient Volume; To Open Three New Centers | https://www.nasdaq.com/articles/lumexa-turns-profit-q3-7-mln-increased-outpatient-volume-open-three-new-centers
- N2 | 2026-11-11 | www.nasdaq.com | Lumexa Imaging (LMRI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/lumexa-imaging-lmri-q3-2026-earnings-call-transcript
- N3 | 2026-11-11 | www.nasdaq.com | What Lumexa Imaging (LMRI) Said on Its Q3 Earnings Call | https://www.nasdaq.com/articles/what-lumexa-imaging-lmri-said-its-q3-earnings-call
- N4 | 2026-08-24 | www.nasdaq.com | Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High? | https://www.nasdaq.com/articles/wall-street-analysts-see-3688-upside-lumexa-lmri-can-stock-really-move-high
- N5 | 2026-08-20 | www.nasdaq.com | Lumexa Imaging (LMRI) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/lumexa-imaging-lmri-q2-2026-earnings-call-transcript
- N6 | 2026-08-13 | www.nasdaq.com | Lumexa Imaging Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/lumexa-imaging-q2-earnings-call-highlights
- N7 | 2026-07-21 | www.nasdaq.com | Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights-terumo-quidelortho-lumexa-imaging-and-brainsway
- N8 | 2026-07-20 | www.nasdaq.com | 4 Medical Products Stocks Poised to Win Despite Industry Headwinds | https://www.nasdaq.com/articles/4-medical-products-stocks-poised-win-despite-industry-headwinds
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


